HSPB3 and prostate carcinoma: Overexpression of HSP27 led to increased survival rates of prostate cancer cells after docetaxel, a microtubule-targeted chemotherapy treatment, while the overexpression of the nonphosphorylatable HSP27 mutant decreased resistance to treatment (166).